PEGS Virtual Summit Speaker Lineup

Confirmed Speakers as of May 1, 2020

KEYNOTE SPEAKERS

Imre Berger, PhD, Director, Max Planck Centre for Minimal Biology, the University of Bristol, United Kingdom

Adrian Bot, PhD, Vice President, Translational Medicine, Kite Pharma, a Gilead Company

Daniel Chen, MD, PhD, CMO, IGM Biosciences

Ivan Correia, MBA, PhD, Head, Global Protein Sciences, AbbVie

Zhimei Du, PhD, Director, Process Development, Merck and Co., Inc.

Stefan Dübel, PhD, Professor & Chair, Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics

Jacob Glanville, PhD, Co-Founder & CEO & President, Distributed Bio Inc.

Mitchell Ho, PhD, Chief, Antibody Therapy Section, Laboratory of Molecular Biology, National Cancer Institute, NIH

Jonathan Kingsbury, PhD, Senior Director, Developability & Preformulation Science, Sanofi

David Lowe, PhD, Senior Director, R&D, Antibody Discovery and Protein Engineering, AstraZeneca

Christian Klein, PhD, Cancer Immunotherapy Discovery, Roche Pharma Research & Early Development, Roche Innovation Center Zurich

Jan Joseph (Jos) Melenhorst, PhD, Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania

Raymond J. Owens, PhD, Professor, Research Complex at Hartwell & Rosalind Franklin Institute, University of Oxford

Paul Parren, PhD, Executive Vice President, Head, R&D, Lava Therapeutics B.V., The Netherlands

Rana Sidhu, PhD, Protein Expression Lead, Early Solutions, UCB, Inc.

Peter Tessier, PhD, Professor, Pharmaceutical Sciences and Chemical Engineering, University of Michigan

Distinguished Faculty

Adam Adler, Professor, Department of Immunology, University of Connecticut Health School of Medicine

Eric S. Alonzo, PhD, Scientist, Process and Analytical Development, bluebird bio

Paolo Arosio, PhD, Professor, Biochemical Engineering, Department of Chemistry and Applied Biosciences, ETH Zurich, Switzerland

Alain Beck, PhD, Senior Director, Biologics CMC and Developability, Pierre Fabre Laboratories, France

George Bou-Assaf, PhD, Scientist, Analytical Development – Product & Technology Development, Biogen

Andrew R.M. Bradbury, MB BS, PhD, CSO, Specifica, Inc.

Iain D. G. Campuzano, Principal Scientist, Discovery Attribute Sciences, Amgen

Abhishek Chatterjee, PhD, Assistant Professor, Chemistry, Boston College

Win Cheung, PhD, Associate Director, Analytical Development, REGENXBIO

Jennifer R. Cochran, PhD, Shriram Chair of Bioengineering; Professor of Bioengineering, and (by courtesy) Chemical Engineering, Stanford University

Matthew Coleman, PhD, Senior Scientist & Group Leader, Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory

James E. Crowe, Jr., MD, Ann Scott Carell Chair & Professor & Director, Vanderbilt University

Dimiter Stanchev Dimitrov, PhD, Infectious Diseases, Director, Center for Antibody Therapeutics, University of Pittsburgh; EVP and CSO, Abound Bio

Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen

Stefan Dübel, PhD, Professor & Chair, Technische Universität Braunschweig, Institute of Biochemistry, Biotechnology and Bioinformatics, Germany

Laurence Fayadat- Dilman, PhD, Senior Director, Merck

Nicolas Fischer, PhD, CEO, Light Chain Bioscience, Novimmune SA, Switzerland

Alex Franzusoff, PhD, CEO, PACT Pharma

William Gillette, PhD, Principal Scientist, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research

Sean Hunter, Researcher, Bioengineering Stanford University

Christos Kyratsous, PhD, VP, Research, Regeneron Pharmaceuticals Inc.

Jonathan R. Lai, PhD, Professor, Department of Biochemistry, Albert Einstein College of Medicine

David Lowe, PhD, Senior Director, R&D, Antibody Discovery and Protein Engineering, AstraZeneca

Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering, William Harvey Research Institute, Queen Mary University of London, United Kingdom

Saleha Patel, PhD, Senior Research Scientist, Protein Science, Discovery Biology, AstraZeneca

Christoph Rader, PhD, Professor, Department of Immunology and Microbiology, Florida Campus, Scripps Research

G. Jonah Rainey, PhD, Vice President, Antibody Therapeutics, Gritstone Oncology, Inc.

Jesse Rinehart, PhD, Associate Professor, Cellular & Molecular Physiology, Systems Biology Institute, Yale University School of Medicine

Marco Ruella, MD, Clinical Instructor, Associate Director, Dr. June’s Laboratory, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania

Stefan R. Schmidt, PhD, MBA, COO, Head, Operations, BioAtrium AG

Susan Sharfstein, PhD, Professor, Nanobioscience, Nanoscale Science and Engineering, SUNY Polytechnic Institute

Mohammad Tabrizi, PhD, Senior Director, Pharmacology, Ascendis Pharma A/S

Alem Truneh, PhD, Co-founder & Chief Technology Officer, ImCheck Therapeutics

Bjørn Voldborg, MSc, Director, CHO Cell Line Development, The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Denmark

Laura Walker, PhD, Director, Antibody Sciences, Adimab, LLC